Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: A children's oncology group phase I consortium study

Pediatric Blood and Cancer

Volumn 54, Issue 4, 2010, Pages 538-545

  Wagner, Lars M ^a   Perentesis, John P ^a   Reid, Joel M ^b   Ames, Matthew M ^b   Safgren, Stephanie L ^b   Nelson Jr , Marvin D ^c   Ingle, Ashish M ^d   Blaney, Susan M ^e   Adamson, Peter C ^f  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b Mayo Clinic   (United States)

^c CHILDREN S HOSPITAL LOS ANGELES   (United States)

^d CHILDREN S ONCOLOGY GROUP   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Cefixime; Oral irinotecan; SN 38; Temozolomide; Vincristine

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; CEFIXIME; CEFPODOXIME; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TEMOZOLOMIDE; VINCRISTINE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ALOPECIA; ALVEOLAR SOFT PART SARCOMA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; BRAIN STEM; CANCER PATIENT; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG TOLERABILITY; EWING SARCOMA; FATIGUE; FEMALE; FEVER; GENOTYPE; GLIOMA; HEPATOBLASTOMA; HUMAN; HYPERBILIRUBINEMIA; HYPERMAGNESEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; LIVER FAILURE; LIVER TOXICITY; LUNG BLASTOMA; LUNG METASTASIS; MALE; MAXIMUM TOLERATED DOSE; MEDULLOBLASTOMA; NAUSEA AND VOMITING; NEUROBLASTOMA; NEUROPATHY; NEUTROPENIA; OSTEOSARCOMA; PHARMACOGENETICS; PHASE 1 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENT DISEASE; SCHOOL CHILD; SOLID TUMOR; SYNOVIAL SARCOMA; THROMBOCYTOPENIA;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CAMPTOTHECIN; CHILD; CHILD, PRESCHOOL; DACARBAZINE; FEMALE; HUMANS; INFANT; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; VINCRISTINE; YOUNG ADULT;

EID: 77649166446     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22407     Document Type: Article

References (30)

1. Bisogno G, Riccardi R, Ruggiero A, et al. Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma. Cancer 2006;106:703-707.
2. Pappo AS, Lyden E, Breitfeld P, et al. Two consecutive phase II windowtrials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: The Children's Oncology Group. J Clin Oncol 2007;25:362-369.
3. Bomgaars LR, Bernstein M, Krailo M, et al. Phase II trial of irinotecan in children with refractory solid tumors: A Children's Oncology Group Study. J Clin Oncol 2007;25:4622-4627.
4. Furman WL, Stewart CF, Poquette CA, et al. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 1999;17:1815-1824.
5. Thompson J, George EO, Poquette CA, et al. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts. Clin Cancer Res 1999;5:3617-3631.
6. Houghton PJ, Stewart CF, Cheshire PJ, et al. Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. Clin Cancer Res 2000;6:4110-4118.
7. Kushner BH, Kramer K, Modak S, et al. Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. J Clin Oncol 2006;24:5271-5276.
8. Wagner LM, Villablanca JG, Stewart CF, et al. Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: A New Approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol 2009;27:1290-1296.
9. Wagner LM, McAllister N, Goldsby RE, et al. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer 2007;48:132-139.
10. Casey DA, Wexler LH, Merchant MS, et al. Irinotecan and temozolomide for Ewing sarcoma: The Memorial Sloan-Kettering experience. Pediatr Blood Cancer 2009; 53: 1029-L 1034.
11. Houghton PJ, Cheshire PJ, Hallman JD II, et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at lowdose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995;36:393-403.
12. Mascarenhas L, Lyden ER, Breitfeld PP, et al. Randomized Phase II window study of two schedules of irinotecan and vincristine in rhabdomyosarcoma patients at first relapse/disease progression. J Clin Oncol 2008;26:542s, (abstr 10013).
13. Furman WL, Crews KR, Billups C, et al.Cefixime allows greater dose escalation of oral irinotecan:Aphase I study in pediatric patientswith refractory solid tumors. J Clin Oncol 2006;24:563-570.
14. Wagner LM, Crews KR, Stewart CF, et al. Reducing irinotecan-associated diarrhea in children. Pediatr Blood Cancer 2008;50:201-207.
15. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the united States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
16. Macdonald DR, Cascino TL, Schold SC Jr, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-1280.
17. Slatter JG, Schaaf LJ, Sams JP, et al. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following intravenous infusion of [(14)C]CPT-11 in cancer patients. Drug Metab Dispos 2000;4:423-433.
18. Gibaldi M, Perrier D. Non-compartmental analysis based on statistical moment therapy. In: Gibaldi M, Perrier D, editors. Pharmacokinetics, 2nd edition. New York: Marcel Dekker; 1982. pp. 409-417.
19. Ong SY, Clarke SJ, Bishop J, et al. Toxicity of irinotecan (CPT-11) and hepto-renal failure. Anticancer Drugs 2001;12:619-625.
20. Schoemaker NE, Kuppens IE, Moiseyenko V, et al. A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer. Br J Cancer 2004;91:1434-1441.
21. Drengler RL, Kuhn JG, Schaaf LJ, et al. Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors. J Clin Oncol 1999;17:685-696.
22. Soepenberg O, Dumez H, Verweij J, et al. Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors. Clin Cancer Res 2005;11:1504-1511.
23. Dumez H, Awada A, Piccart M, et al. A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours. Ann Oncol 2006;17:1158-1165.
24. Crews KR, Stewart CF, Jones-Wallace D, et al. Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy. Clin Cancer Res 2002;8:2202-2209.
25. Wagner LM, Crews KR, Iacono LC, et al. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res 2004;10:840-848.
26. Rubie CJ, Defachellas AS, Morland B, et al. Phase II study of temozolomide in relapsed or refractory high-risk neuroblastoma:A joint Societe Francaise des Cancers de l'Enfant and United Kingdom Children Cancer Study Group-New Agents Group Study. J Clin Oncol 2006;24:5259-5264.
27. Nicholson HS, Kretschmar CS, Krailo M, et al. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: A report from the Children's Oncology Group. Cancer 2007;110:1542-1550.
28. Ramchandani RP, Wang Y, Booth BP, et al. The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity. J Clin Pharmacol 2007;47:78-86.
29. Goetz MP, Safgren S, Goldberg RM, et al.Aphase I dose escalation study of irintecan and oxaliplatin and capecitabine within three UGT1A1 TA promoter cohorts (6/6, 6/7, and 7/7). J Clin Oncol 2005;23:16S, (abstr 2014).
30. Stewart CF, Panetta JC, O'Shaughnessy M, et al. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan. J Clin Oncol 2007;25:2594-2600.